Status:
UNKNOWN
Efficacy of Albumin Plus Midodrine v/s Albumin Alone in Reducing Incidence of Paracentesis Induced Circulatory Dysfunctions in ACLF Patients.
Lead Sponsor:
Institute of Liver and Biliary Sciences, India
Conditions:
Acute-On-Chronic Liver Failure
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The patients with ACLF having Ascites who require ascitic tapping will undergone ascitic tapeither under albumin cover alone or with midodrine. The patient will be monitored for complication and chang...
Detailed Description
OBJECTIVE: Primary objective: Incidence of Paracentesis induced circulatory dysfunction in patients undergoing modest volume paracentesis (MVP) (\>3 and \<5 litres) with midodrine plus 25% albumin v/...
Eligibility Criteria
Inclusion
- \- ACLF patients (as per APASL definition) with grade II/III ascites
Exclusion
- Age \< 18 or \>75 years
- Hepatocellular carcinoma
- Extrahepatic portal vein obstruction
- Non cirrhotic ascites
- Serum creatinine \>1.5mg/dl
- Refractory septic shock
- Beta blockersPortal vein thrombosis
- Grade 3-4 HE
- Pregnancy or Lactation
- Active variceal bleed
- Respiratory, cardiac, renal failure
- Uncontrolled hypertension
- Severe coagulopathy
- Refusal to participate
Key Trial Info
Start Date :
July 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2021
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04474262
Start Date
July 15 2020
End Date
March 31 2021
Last Update
July 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, India, 110070